10-K: Vaso Corporation Reports Increased Revenue but Lower Net Income in 2024 Annual Report

Vaso Corporation's 2024 annual report reveals a revenue increase of 7.1% to $86.8 million, but a decrease in net income due to higher operating expenses.

Summary

• Vaso Corporation's 2024 total revenues increased by $5.743 million, or 7.1%, reaching $86.767 million.
• Net income decreased by $3.854 million to $951,000, primarily due to higher operating expenses.
• The IT segment's revenue rose by $2.583 million, or 6.4%, to $42.954 million, driven by managed network services.
• Professional sales service segment revenue increased by $3.515 million, or 9.3%, to $41.335 million due to a higher commission rate and equipment volume.
• Equipment segment revenue decreased by 12.5% to $2.478 million due to lower US operations and China sales.
• The company's gross profit increased by $1.457 million, or 2.9%, to $52.050 million.
• Operating income decreased by $3.910 million, or 93%, to $285,000, mainly due to increased corporate expenses and operating losses in the IT segment.
• Adjusted EBITDA decreased by $4.093 million to $1.001 million.
• The company had net operating loss carryforwards of approximately $19 million at December 31, 2024.
• Cash and cash equivalents were $26.371 million at December 31, 2024, and approximately $32.4 million at March 24, 2025.
• The company expects to generate sufficient cash flow from operations to satisfy its obligations for the next twelve months.

Sentiment

Score: 5

Explanation: The document presents mixed results, with increased revenue offset by decreased net income and operating income. The outlook is cautiously optimistic, but risks remain.

Positives

• Total revenues increased by 7.1% to $86.767 million in 2024.
• The IT segment's revenue rose by 6.4% to $42.954 million, driven by managed network services.
• Professional sales service segment revenue increased by 9.3% to $41.335 million due to a higher commission rate and equipment volume.
• Gross profit increased to $52.050 million, or 60.0% of revenue.
• Cash and cash equivalents were $26.371 million at the end of 2024 and approximately $32.4 million at March 24, 2025.
• The GEHC Agreement extends through December 31, 2026.

Negatives

• Net income decreased to $951,000 in 2024 from $4.805 million in 2023.
• Equipment segment revenue decreased by 12.5% to $2.478 million due to lower US operations and China sales.
• Operating income decreased to $285,000.
• Adjusted EBITDA decreased to $1.001 million.

Risks

• The company's ability to sustain profitability is dependent on the GEHC Agreement, which is subject to early termination.
• The company faces competition in all segments of its business.
• Data security incidents or disruptions in information technology systems could damage the business.
• The company depends on management and other key personnel.
• The company may not continue to receive necessary clearances or approvals from the US FDA or foreign authorities for its medical devices.
• The company has foreign operations and is subject to the associated risks of doing business in foreign countries.
• The company depends on several suppliers for the supply of certain products.
• The company may not have adequate intellectual property protection.
• The company's common stock is subject to price volatility.
• The company does not intend to pay dividends in the foreseeable future.

Future Outlook

The Company expects to generate sufficient cash flow from operations to satisfy its obligations for the next twelve months.

Industry Context

The company operates in the healthcare equipment and information technology industries, facing competition from other diagnostic imaging equipment manufacturers, software solution providers, and managed network service providers.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Comparable companies in the diagnostic imaging market include Siemens, Philips, Canon, and Hologic.
• In the healthcare IT VAR business, competitors include Agfa Healthcare, McKesson, Philips, and Carestream Health.
• In managed network services, competitors include Verizon, AT&T, CenturyLink, IBM, and Cisco Resellers.

Legal Proceedings

• The Company is currently, and has been in the past, a party to various routine legal proceedings, primarily employee related matters, incident to the ordinary course of business.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and operating income.
• Employees may be affected by cost control measures and potential changes in business strategy.
• Customers may be impacted by changes in product and service offerings.
• Suppliers may be affected by changes in the company's supply chain and manufacturing operations.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• Continue to effectively control operating costs in the current inflationary environment.
• Continue to expand product and service offerings as well as market penetration in all business segments.
• Maintain and improve business performance in the professional sales service segment.
• Maintain and grow the equipment business by increasing efficiency and continue to transform the operation and explore new revenue models.
• Continue to seek accretive partnership opportunities.
• Explore options in capital markets for the stock.

Key Dates

Keywords

revenue, Vaso Corporation, GEHC Agreement, net income, IT segment, medical devices, financial results, EBITDA, healthcare, equipment segment